Pharmacological modulation of the renin-angiotensin-aldosterone-kinin system is a promising therapeutic target for mitigating cardiovascular-renal complications in patients with diabetes mellitus.
Diabetes mellitus is associated with an inordinately high risk of virtually all manifestations of cardiovascular-renal disease including atherosclerotic coronary and peripheral vascular disease, congestive heart failure, stroke, nephropathy, and cardiomyopathy unassociated with coronary heart disease. Abnormalities in the renin-angiotensin-aldosterone-kinin (RAAK) cascade have been implicated in the pathogenesis and clinical expression of these cardiovascular-renal sequelae. Thus, pharmacological modulation of the RAAK system is an attractive therapeutic target in diabetes mellitus. Indeed, emerging data from human clinical studies appear to confirm this thesis.
Flack et al. (Thu,) conducted a review in Diabetes mellitus. Pharmacological modulation of the RAAK system was evaluated. Pharmacological modulation of the renin-angiotensin-aldosterone-kinin system is a promising therapeutic target for mitigating cardiovascular-renal complications in patients with diabetes mellitus.